[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100433763":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":62,"collaborators":42,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":42,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":42,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":42,"overallStatus":47,"whyStopped":42,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group B","EXPERIMENTAL","Nebulized Bupivacaine 0.50% 0.50 mg.kg-1",[13],"Drug: Bupivacaine Hydrochloride",{"label":15,"type":16,"description":17,"interventionNames":18},"Group C","PLACEBO_COMPARATOR","Same volume of nebulized saline placebo",[19],"Other: 0.9% saline",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Bupivacaine Hydrochloride","Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1",[9],[27],"marcaine",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"0.9% saline","Preoperative nebulized same volume of saline placebo",[15],[33],"Normal saline",[35],{"name":36,"affiliation":5,"role":37},"Omar Soliman, MD","STUDY_DIRECTOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","01101266040",null,"omarmakram347@yahoo.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Assiut university hospital","RECRUITING","Asyut","Assuit","Assuit universi","Egypt","EG",{"type":54,"coordinates":55},"Point",[56,57],31.18368,27.18096,{"lat":57,"lon":56},[60],{"name":61,"role":40,"phone":41,"phoneExt":42,"email":43},"Omar Soliman",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"PRINCIPAL_INVESTIGATOR","Omar Makram Soliman","Lecturer of anesthesia and ICU","100433763","phase-3-nebulized-bupivacaine-analgesia-for-cleft-palate-repair-100433763",false,"NCT04928352","Nebulized Bupivacaine Analgesia for Cleft Palate Repair","Preemptive Nebulized Bupivacaine for Pain Control After Cleft Palate Repair in Children: A Randomized Double Blind Controlled Trial","Inclusion Criteria:\n\n* Children (age 1-7 years) of American Society of Anaesthesiologists physical status (ASA) I-II\n* Elective cleft palate repair ± cleft lip surgery under general anesthesia .\n\nExclusion Criteria:\n\n* Coronary artery disease\n* Hypertension\n* Developmental delay\n* Allergy to study drug","ALL","1 Year","7 Years",{"count":77,"type":78},60,"ESTIMATED","INTERVENTIONAL",[81],"PHASE3","In this study we introduce a potent local anesthetic; bupivacaine 0.5% in 0.5 mg\u002Fkg dose by nebulization as a preemptive analgesia to compare efficacy and safety in children with cleft palate repair.",[84],"Cleft Palate","2025-12-27",{"date":87,"type":88},"2026-01-02","ACTUAL",{"date":90,"type":88},"2021-06-14",{"date":92,"type":78},"2026-09-20",{"name":5,"class":6},1]